Skip to main content
OpenTrials
Completed

NCT Number: NCT00083421

Effects of ONO-2506PO in Patients With Alzheimer's Disease

The purpose of this study is to establish the presence of an effect of treatment with ONO-2506PO in patients with Alzheimer's Disease, based upon cognitive and global scales.

Completed

Looking for future studies?

Notify Me

Key information

Conditions

Alzheimer's Disease Alzheimer Disease Brain Diseases Central Nervous System Diseases Dementia Mental Disorders Nervous System Diseases Neurocognitive Disorders Neurodegenerative Diseases Tauopathies

Age range

50 year–90 year

Sex eligibility

All sexes

Study type

Interventional

Phase

Phase 2

Primary location

Inova Health Research, Inc., Kelowna, British Columbia, Canada

Loading trial locations.

Who can participate

Healthy volunteers accepted: No

Only the study team can determine whether someone qualifies for participation.

Inclusion criteria

  • Diagnosis of probable Alzheimer's Disease using NINCDS/ADRDA criteria
  • Standardized MMSE Score of 13 to 24 points (inclusive)
  • Modified Hachinski score equal or less than 4

Exclusion criteria

  • Serious systemic disease that may preclude survival to study completion
  • Other illnesses that may include dementive features

Treatment and study plan

ONO-2506PO

Drug

Primary outcomes

  1. Cognitive Function Scale

  2. Global Function Scale

Secondary outcomes

  1. ADL Scale

  2. Psychiatric Symptom Scale

Sponsors and collaborators

Lead sponsor

Ono Pharma USA Inc

Industry

Registry information

Important dates

Study start
2004
Study completion
2007
First posted
Jun 18, 2004
Registry last updated
Jun 13, 2012

OpenTrials presents study information sourced from ClinicalTrials.gov. The official registry record should be consulted for the latest information.

View the official ClinicalTrials.gov record (opens in a new tab)

This listing is for discovery and informational purposes only. It is not medical advice, does not guarantee that a study is recruiting, and does not determine eligibility. Contact the study team and a qualified healthcare professional when considering participation.

Related clinical trials

Published trials that share one or more normalized conditions with this study.